← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Biogen stabilized revenue, but profit and free cash flow fell as the pipeline and launch portfolio still need to prove growth.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +2.2% to $9.89BNote
- Profitability — Net income -20.8% to $1.29BWatch
- Cash quality — FCF -24.7% to $2.05BWatch
- Margins — Net margin -380 bpsWatch
- Capital — Debt -0.1%; equity +9.2%Note
- Insiders — 1 open-market buy / 3 sellsWatch
Business
Biogen is a global biopharmaceutical company focused on serious and complex diseases, with marketed therapies in multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, ALS, Alzheimer's disease collaborations, postpartum depression collaboration economics, anti-CD20 rights, and biosimilars.
Where the revenue comes from
Fiscal 2025, as BIOGEN INC. reports it. History and quarterly detail are in the app.
- Product revenue, net$7.1B
- Subtotal: Multiple Sclerosis$4.0B
- Subtotal: Rare Disease$2.2B
- Revenue from anti-CD20 therapeutic programs$1.9B
- Total Fumarate$1.4B
Leadership changes
From BIOGEN INC.'s own filings, the day they're filed.
- Caroline Dorsa · Directors · departureeff. 2026-02-11
- Sean Godbout · President · appointmenteff. 2025-03-01
- Robin Kramer · principal accounting officer as of the · appointmenteff. 2025-03-01
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOGEN INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.